Track topics on Twitter Track topics that are important to you
Concurrent with an $11mm Series A, NuProbe Inc. spun off from Harvard University’s Wyss Institute and licensed worldwide rights to a DNA nanotechnology-based variant-detecting method.
Molecular diagnostics firm NuProbe Inc. raised $11mm in its Series A financing led by Sequoia China and Serica Partners, which were joined by WuXi AppTec Corporate Ventures.
(Wyss Institute for Biologically Inspired Engineering at Harvard) NuProbe Global will commercialize the Wyss Institute's DNA nanotechnology-based variant-detecting method as a fast, low-cost and multi...
A round of Series A financing pulled in $11 million for Cambridge, Mass.-based NuProbe, an early-stage molecular diagnostics -More-
Molecular diagnostics startup to expand reach of precision medicine NuProbe, an early stage molecular diagnostics company, raised $11 million to continue development of...
We have published hundreds of NuProbe news stories on BioPortfolio along with dozens of NuProbe Clinical Trials and PubMed Articles about NuProbe for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of NuProbe Companies in our database. You can also find out about relevant NuProbe Drugs and Medications on this site too.